Mark E. Sims - 06 Jul 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Commercial Officer
Issuer ticker: CADL
Reported as of: 06 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jul 2026, 16:12:32 UTC
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for Mark E. Sims

Key filing fact

Mark E. Sims filed Form 4 for Candel Therapeutics, Inc. (CADL) on 08 Jul 2026.

Key facts

This page summarizes Mark E. Sims's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2026, 16:12.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002139479 Primary reporting owner

Sims Mark E.

Relationship: Chief Commercial Officer
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK STREET, SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for Mark E. Sims
Signature date: 08 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +285,000
Change %
Price: $0.000000^*
Shares after: 285,000
Date: 06 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 285,000
Exercise price: $10.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying this option shall vest and become exercisable on July 6, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.